![Christopher Moyses](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Moyses
Nessuna posizione attualmente
Storia della carriera di Christopher Moyses
Precedenti posizioni note di Christopher Moyses
Società | Posizione | Inizio | Fine |
---|---|---|---|
Kind Consumer Ltd.
![]() Kind Consumer Ltd. Pharmaceuticals: MajorHealth Technology Kind Consumer Ltd. operates as a healthcare research and development company which focuses on the inhalation technologies. It offers Voke, Oxette, Evo, and Polykind products. The company was founded by Alexander Thomas Hearn in 2006 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 17/07/2013 | 19/04/2017 |
Direttore Tecnico/Scientifico/R&S | 03/05/2011 | 19/04/2017 | |
Senexis Ltd.
![]() Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | Presidente | 09/02/2010 | 17/07/2013 |
AstraZeneca, Inc.
![]() AstraZeneca, Inc. BiotechnologyHealth Technology Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines. | Corporate Officer/Principal | - | - |
G.D. Searle LLC | Corporate Officer/Principal | - | - |
Amylin Pharmaceuticals, Inc.
![]() Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Direttore Tecnico/Scientifico/R&S | - | - |
Consigliere Generale | - | - | |
Oxford GlycoSciences Plc
![]() Oxford GlycoSciences Plc Pharmaceuticals: MajorHealth Technology Oxford Glycosciences Plc provides biopharmaceutical products. The company develops and manufactures novel products for the diagnosis and treatment of human disease. Its products include bayer, pioneer hi-breddupont, medarex, genmab, glaxosmithkline, neogenesis and pfizer. It was founded in 1988. The company is headquartered in Abingdon, UK. | Direttore/Membro del Consiglio | 01/01/1996 | - |
Direttore Tecnico/Scientifico/R&S | 01/01/1996 | - | |
Pharmagene Plc | Direttore Tecnico/Scientifico/R&S | - | - |
Ardana Plc
![]() Ardana Plc Pharmaceuticals: MajorHealth Technology Ardana Plc developed pharmaceuticals products. It offered Invicorp, an intracavernosal injectable combination of phentolamine mesilate and vasoactive intestinal polypeptide for the treatment of male erectile dysfunction. The company was founded in 2000 and was headquartered in Bristol, the United Kingdom. | Direttore/Membro del Consiglio | 27/06/2007 | - |
Pulmagen Therapeutics (Synergy) Ltd.
![]() Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Direttore/Membro del Consiglio | 01/01/2006 | - |
Direttore Tecnico/Scientifico/R&S | 01/01/2006 | - |
Formazione di Christopher Moyses
University of Cambridge | Graduate Degree |
University of Oxford | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 9 |
Stati Uniti | 4 |
Posizioni
Chief Tech/Sci/R&D Officer | 5 |
Director/Board Member | 4 |
Corporate Officer/Principal | 2 |
Settori
Health Technology | 8 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 9 |
---|---|
Pulmagen Therapeutics (Synergy) Ltd.
![]() Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |
Ardana Plc
![]() Ardana Plc Pharmaceuticals: MajorHealth Technology Ardana Plc developed pharmaceuticals products. It offered Invicorp, an intracavernosal injectable combination of phentolamine mesilate and vasoactive intestinal polypeptide for the treatment of male erectile dysfunction. The company was founded in 2000 and was headquartered in Bristol, the United Kingdom. | Health Technology |
Pharmagene Plc | Health Technology |
Oxford GlycoSciences Plc
![]() Oxford GlycoSciences Plc Pharmaceuticals: MajorHealth Technology Oxford Glycosciences Plc provides biopharmaceutical products. The company develops and manufactures novel products for the diagnosis and treatment of human disease. Its products include bayer, pioneer hi-breddupont, medarex, genmab, glaxosmithkline, neogenesis and pfizer. It was founded in 1988. The company is headquartered in Abingdon, UK. | Health Technology |
Senexis Ltd.
![]() Senexis Ltd. BiotechnologyHealth Technology Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning. It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease. | Health Technology |
Amylin Pharmaceuticals, Inc.
![]() Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Kind Consumer Ltd.
![]() Kind Consumer Ltd. Pharmaceuticals: MajorHealth Technology Kind Consumer Ltd. operates as a healthcare research and development company which focuses on the inhalation technologies. It offers Voke, Oxette, Evo, and Polykind products. The company was founded by Alexander Thomas Hearn in 2006 and is headquartered in London, the United Kingdom. | Health Technology |
G.D. Searle LLC | |
AstraZeneca, Inc.
![]() AstraZeneca, Inc. BiotechnologyHealth Technology Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines. | Health Technology |
- Borsa valori
- Insiders
- Christopher Moyses
- Esperienza